MNG434
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.510
- OXIDATIVE_PHOSPHORYLATION+0.479
- CHOLESTEROL_HOMEOSTASIS+0.436
- MYC_TARGETS_V1+0.413
- ADIPOGENESIS+0.382
- UNFOLDED_PROTEIN_RESPONSE+0.332
- ANDROGEN_RESPONSE+0.322
- DNA_REPAIR+0.321
- MTORC1_SIGNALING+0.308
- MITOTIC_SPINDLE+0.284
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.371
- INFLAMMATORY_RESPONSE-0.363
- KRAS_SIGNALING_DN-0.291
- TNFA_SIGNALING_VIA_NFKB-0.284
- HEDGEHOG_SIGNALING-0.274
- IL6_JAK_STAT3_SIGNALING-0.258
- PANCREAS_BETA_CELLS-0.228
- MYOGENESIS-0.223
- HYPOXIA-0.221
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.219
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG458 | — | — | 0.972 |
| 2 | MNG1053 | — | — | 0.860 |
| 3 | R122 | — | — | 0.857 |
| 4 | MNG1038 | — | — | 0.843 |
| 5 | SRR934941 | — | — | 0.830 |
| 6 | E3887082-4C43-426C-8580-ECAA4EFEC577 | — | — | 0.829 |
| 7 | MNG1017 | — | — | 0.826 |
| 8 | F2FCC449-3487-474C-82A6-8F2ED71E41BC | — | — | 0.824 |
| 9 | MNG570 | — | — | 0.824 |
| 10 | 10EE3CFC-9230-40BA-9C9F-77949BA763CC | — | — | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.510 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.479 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.436 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.413 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.382 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.332 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.322 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.321 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.308 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.284 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.233 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.228 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.227 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.226 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.225 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.213 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.176 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.170 | Idelalisib | — uncovered |
| PEROXISOME | 0.134 | Idelalisib | — uncovered |